Erythropoiesis-stimulating agent hyporesponsiveness and malignancy development in patients with non-dialysis chronic kidney disease: a prospective cohort study
Both initial ESA hyporesponsiveness and subsequent declines in responsiveness were significantly associated with the development of malignancy in patients with NDD-CKD. ESA hyporesponsiveness may serve as a clinical marker that reflects an increased risk of undiagnosed malignancy.
Authors
- Nobuhiro Hashimoto (ORCID: https://orcid.org/0000-0002-1221-1900)
- Ichiei Narita (ORCID: https://orcid.org/0000-0001-7692-3096)
- Tatsuo Kagimura (ORCID: https://orcid.org/0000-0001-9856-1006)
- Terumasa Hayashi (ORCID: https://orcid.org/0000-0002-0512-7022)
Institutions
- Osaka City General Hospital (JP)
- Translational Research Informatics Center (Japan) (JP)
- Niigata University (JP)
Publication Details
- Journal
- Clinical and Experimental Nephrology
- Published
- 2025-10-27
- DOI
- https://doi.org/10.1007/s10157-025-02769-7
- Primary Topic
- Erythropoietin and Anemia Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00